XML 39 R28.htm IDEA: XBRL DOCUMENT
v3.25.2

Segment Information (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
Segment Reporting [Abstract] |
Schedule of Reconciliation of Segment Loss Before Income Taxes and Total Consolidated Loss Before Income Taxes | The following table presents selected financial information with respect to the Company’s single operating segment for the three and six months ended June 30, 2025 and 2024 (in thousands):
| Therapeutics Segment
| Three Months Ended June 30, |  | Six Months Ended June 30, |  |
| 2025 |  | 2024 |  | 2025 |  | 2024 |  |
Expenses |  |  |  |  |  |  |  |  |
External research and development expenses - TV programs, including cost sharing | $ | 37,594 |  |  | $ | 30,247 |  |  | $ | 84,052 |  |  | $ | 65,931 |  |  |
External research and development expenses - small molecule programs, including cost sharing | 2,787 |  |  | 12,596 |  |  | 11,641 |  |  | 25,717 |  |  |
Other research and development expenses | 22,060 |  |  | 14,504 |  |  | 42,706 |  |  | 30,386 |  |  |
Personnel related research and development expenses | 40,255 |  |  | 34,052 |  |  | 80,524 |  |  | 76,381 |  |  |
Total research and development expenses | 102,696 |  |  | 91,399 |  |  | 218,923 |  |  | 198,415 |  |  |
Personnel related general and administrative expenses | 20,115 |  |  | 17,105 |  |  | 38,853 |  |  | 36,190 |  |  |
Other general and administrative expenses | 12,152 |  |  | 8,089 |  |  | 22,767 |  |  | 14,240 |  |  |
Total general and administrative expenses | 32,267 |  |  | 25,194 |  |  | 61,620 |  |  | 50,430 |  |  |
Segment operating expenses | 134,963 |  |  | 116,593 |  |  | 280,543 |  |  | 248,845 |  |  |
Segment gain from divestiture of small molecule programs | — |  |  | — |  |  | — |  |  | 14,537 |  |  |
Segment loss from operations | (134,963) |  |  | (116,593) |  |  | (280,543) |  |  | (234,308) |  |  |
Segment interest and other income, net | 10,844 |  |  | 17,567 |  |  | 23,454 |  |  | 33,480 |  |  |
Segment loss before income taxes | $ | (124,119) |  |  | $ | (99,026) |  |  | $ | (257,089) |  |  | $ | (200,828) |  |  |

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration